Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

krka d.d. novo mesto - atorvastatina calcica trihidrato; amlodipino besilato - comprimido recubierto con pelÍcula - 10 mg/10 mg - atorvastatina calcica trihidrato 10 mg; amlodipino besilato 10 mg - atorvastatina y amlodipino

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios normon s.a. - atorvastatina calcica trihidrato; amlodipino besilato - comprimido recubierto con pelÍcula - 10 mg/10 mg - atorvastatina calcica trihidrato 10 mg; amlodipino besilato 10 mg - atorvastatina y amlodipino

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios normon s.a. - atorvastatina calcica trihidrato; amlodipino besilato - comprimido recubierto con pelÍcula - 10 mg/5 mg - atorvastatina calcica trihidrato 10 mg; amlodipino besilato 5 mg - atorvastatina y amlodipino

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

teva b.v. - atorvastatina calcica trihidrato; ezetimiba - comprimido recubierto con pelÍcula - 10 mg/10 mg - atorvastatina calcica trihidrato 10 mg; ezetimiba 10 mg - atorvastatina y ezetimiba

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

teva b.v. - atorvastatina calcica trihidrato; ezetimiba - comprimido recubierto con pelÍcula - 20 mg/10 mg - atorvastatina calcica trihidrato 20 mg; ezetimiba 10 mg - atorvastatina y ezetimiba

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

teva b.v. - atorvastatina calcica trihidrato; ezetimiba - comprimido recubierto con pelÍcula - 40 mg/10 mg - atorvastatina calcica trihidrato 40 mg; ezetimiba 10 mg - atorvastatina y ezetimiba

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

teva b.v. - atorvastatina calcica trihidrato; ezetimiba - comprimido recubierto con pelÍcula - 80 mg/10 mg - atorvastatina calcica trihidrato 80 mg; ezetimiba 10 mg - atorvastatina y ezetimiba

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atorvastatin calcium trihydrate, quantity: 43.38 mg (equivalent: atorvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: calcium carbonate; microcrystalline cellulose; hyprolose; croscarmellose sodium; polysorbate 80; magnesium stearate; lactose monohydrate; candelilla wax; titanium dioxide; macrogol 8000; hypromellose; purified talc; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atorvastatin calcium trihydrate, quantity: 10.845 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; magnesium stearate; lactose monohydrate; calcium carbonate; croscarmellose sodium; polysorbate 80; candelilla wax; titanium dioxide; macrogol 8000; hypromellose; purified talc; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atorvastatin calcium trihydrate, quantity: 86.76 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; polysorbate 80; lactose monohydrate; magnesium stearate; calcium carbonate; hyprolose; microcrystalline cellulose; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate; titanium dioxide; macrogol 8000; hypromellose; purified talc - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.